Adrenergic beta-1 Receptor Antagonists
"Adrenergic beta-1 Receptor Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs that bind to and block the activation of ADRENERGIC BETA-1 RECEPTORS.
| Descriptor ID |
D058671
|
| MeSH Number(s) |
D27.505.519.625.050.200.200.100 D27.505.696.577.050.200.200.100
|
| Concept/Terms |
Adrenergic beta-1 Receptor Antagonists- Adrenergic beta-1 Receptor Antagonists
- Adrenergic beta 1 Receptor Antagonists
- Adrenergic beta1-Antagonists
- Adrenergic beta1 Antagonists
- beta1-Antagonists, Adrenergic
- beta-1 Adrenergic Blocking Agents
- beta 1 Adrenergic Blocking Agents
- Adrenergic beta-1 Antagonists
- Adrenergic beta 1 Antagonists
- Antagonists, Adrenergic beta-1
- beta-1 Antagonists, Adrenergic
- Adrenergic beta-1 Receptor Blockers
- Adrenergic beta 1 Receptor Blockers
|
Below are MeSH descriptors whose meaning is more general than "Adrenergic beta-1 Receptor Antagonists".
Below are MeSH descriptors whose meaning is more specific than "Adrenergic beta-1 Receptor Antagonists".
This graph shows the total number of publications written about "Adrenergic beta-1 Receptor Antagonists" by people in this website by year, and whether "Adrenergic beta-1 Receptor Antagonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 0 | 1 | 1 |
| 2003 | 1 | 0 | 1 |
| 2010 | 1 | 0 | 1 |
| 2011 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2014 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2018 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
| 2020 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Adrenergic beta-1 Receptor Antagonists" by people in Profiles.
-
The effects of normoxic endurance exercise on erythropoietin (EPO) production and the impact of selective ?1 and non-selective ?1?+??2 adrenergic receptor blockade. Eur J Appl Physiol. 2021 May; 121(5):1499-1511.
-
The effects of ?1 and ?1+2 adrenergic receptor blockade on the exercise-induced mobilization and ex vivo expansion of virus-specific T cells: implications for cellular therapy and the anti-viral immune effects of exercise. Cell Stress Chaperones. 2020 11; 25(6):993-1012.
-
Variants in ADRB1 and CYP2C9: Association with Response to Atenolol and Losartan in Marfan Syndrome. J Pediatr. 2020 07; 222:213-220.e5.
-
Metoprolol for the Prevention of Acute Exacerbations of COPD. N Engl J Med. 2019 12 12; 381(24):2304-2314.
-
Genome-Wide Meta-Analysis of Blood Pressure Response to ?1-Blockers: Results From ICAPS (International Consortium of Antihypertensive Pharmacogenomics Studies). J Am Heart Assoc. 2019 08 20; 8(16):e013115.
-
Genome-Wide Association Approach Identified Novel Genetic Predictors of Heart Rate Response to ?-Blockers. J Am Heart Assoc. 2018 02 24; 7(5).
-
Comparative Efficacy of Nebivolol and Metoprolol to Prevent Tachycardia-Induced Cardiomyopathy in a Porcine Model. Tex Heart Inst J. 2016 Dec; 43(6):477-481.
-
Targeting the sympatho-adrenergic link in chronic rheumatic mitral regurgitation: assessing the role of oral beta-blockers. Cardiovasc Ther. 2016 Aug; 34(4):261-7.
-
Predictors for glucose change in hypertensive participants following short-term treatment with atenolol or hydrochlorothiazide. Pharmacotherapy. 2014 Nov; 34(11):1132-40.
-
Echocardiographic methods, quality review, and measurement accuracy in a randomized multicenter clinical trial of Marfan syndrome. J Am Soc Echocardiogr. 2013 Jun; 26(6):657-66.